Geriatric Oncology, Nutrition, Nutrition Assessment, Oncology
Conditions
Keywords
G-CSF, CARG, Frailty, Mini Nutritional Assessment (MNA)
Brief summary
This study aims to evaluate the ability of G8, CARG, and Frailty scales to predict chemotherapy-related toxicity and the need for G-CSF in elderly cancer patients. It also investigates their correlation with nutritional biomarkers (albumin, prealbumin, hemoglobin, CRP) and the Mini Nutritional Assessment (MNA) test.
Detailed description
Background: Aging is associated with decreased physiological reserves, making elderly cancer patients more vulnerable to chemotherapy toxicity (CT). Traditional performance scales like ECOG may be insufficient for treatment decisions. Tools such as G8, Clinical Frailty Scale (CFS), and the Cancer and Aging Research Group (CARG) score are practical screening instruments recommended by ASCO and SIOG, yet their combined predictive accuracy for CT and granulocyte colony-stimulating factor (G-CSF) usage remains underexplored. Objectives: This prospective study aims to evaluate the predictive performance of the G8, CARG, and Frailty scales-alone and in combination with nutritional biomarkers (albumin, prealbumin, hemoglobin, CRP)-in forecasting chemotherapy-related toxicity and G-CSF need. It also investigates the correlation between these geriatric assessment tools and Mini Nutritional Assessment (MNA) scores. Methods: The study will be conducted at Çanakkale University Medical Faculty Oncology Outpatient Clinic. Patients aged 65 and above with a planned chemotherapy regimen will be recruited. Before the first chemotherapy cycle, patients will undergo G8, CARG, Frailty, and MNA assessments. Nutritional biomarkers will be extracted from pre-treatment routine lab tests. Chemotherapy toxicity and G-CSF requirement will be monitored across treatment cycles. ROC, correlation, and regression analyses will be conducted to evaluate predictive validity.
Interventions
None listed
Sponsors
Çanakkale Onsekiz Mart University
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 65 years * Diagnosed with solid tumor malignancy * Planned to undergo at least two cycles of adjuvant, neoadjuvant, or metastatic chemotherapy * Clinically stable condition * Provided written informed consent
Exclusion criteria
* Presence of hematological malignancies * Concurrent hormonal therapy, targeted therapy, immunotherapy, or radiotherapy * Acute infection or advanced organ failure (cardiac, hepatic, renal) * Cognitive or psychiatric impairment preventing test participation * Prior treatment with G-CSF
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Side effects of chemotherapy | From enrollment to 6 month |
Countries
Turkey (Türkiye)
Outcome results
None listed